Cancer and Molecular Therapies

Dr. Merav Cohen

Immunotherapy targets using single-cell analysis

Tissue development, homeostasis and pathologies are highly regulated processes orchestrated by intercellular crosstalk between immune cell niche and tissue resident cells, not necessarily from the immune lineage Dr Cohen incorporates stateof-the -art single cell RNAsequencing technologies, murine models, clinical approaches and advanced computational methods in order to reveal the molecular signature of interacting cells that drives https://www.mcohenlab.com / exclusive cell function The lab aims to assess similarities and discrepancies in interactome molecular signature between tissue development process and cancerous conditions in order to identify novel immunotherapy targets, directed against intercellular crosstalk .

Dr. Cohen, Department of Clinical Microbiology and Immunology, received her MSc in the field of Cancer Immunology from the Faculty of Engineering Sciences, Department of Biotechnology Engineering, BenGurion University of the Negev, in a direct MSc track for excellent students, and graduated summa cum laude . She received her PhD in the field of ‘NeuroImmunology’ from the Department of Neurobiology, the Weizmann Institute of Science. Dr. Cohen performed her postdoctoral training in the field of ‘Immuno -Genomics’, at the Department of Immunology at the Weizmann Institute of Science, and at the Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, in the field of ‘Cancer Immunology’. She won the Feinberg Graduate School Prize for Outstanding Achievements in Postdoctoral Research, and the Ministry of Science and Technology Scholarship for Postdoctoral Fellows in Applied and Engineering Science.